Montelukast
- Generic Name
- Montelukast
- Brand Names
- Singulair
- Drug Type
- Small Molecule
- Chemical Formula
- C35H36ClNO3S
- CAS Number
- 158966-92-8
- Unique Ingredient Identifier
- MHM278SD3E
- Background
Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs. Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticos...
- Indication
Montelukast is indicated for:
...
- Associated Conditions
- Asthma, Exercise-Induced Bronchospasm, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 46
- Registration Number
- NCT00636207
Controlled Trial on Effect of Montelukast Treatment in Children With Obstructive Sleep Apnea Syndrome
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- University of Louisville
- Registration Number
- NCT00599534
- Locations
- 🇺🇸
University of Louisville Pediatric Sleep Medicine Center, Louisville, Kentucky, United States
🇺🇸University of Louisville Pediatrics Sleep Medicine Center, Louisville, Kentucky, United States
The Role of Montelukast in Rhinitis and Sleep
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2014-10-21
- Lead Sponsor
- Penn State University
- Target Recruit Count
- 31
- Registration Number
- NCT00590772
Effect of Addition of Oral Montelukast to Standard Treatment in Acute Moderate to Severe Asthma in Children
- First Posted Date
- 2007-11-30
- Last Posted Date
- 2008-11-14
- Target Recruit Count
- 116
- Registration Number
- NCT00565955
- Locations
- 🇮🇳
All India Institute of Medical Sciences, New Delhi, Delhi, India
Montelukast as a Controller of Atopic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2007-11-16
- Lead Sponsor
- University of Helsinki
- Target Recruit Count
- 61
- Registration Number
- NCT00559546
- Locations
- 🇫🇮
Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- 1st Allergy & Clinical Research Center
- Target Recruit Count
- 20
- Registration Number
- NCT00557284
- Locations
- 🇺🇸
1st Allergy & Clinical Research Centers, Thornton, Colorado, United States
Leukotriene Receptor Antagonists or Steroids in Pre-School Asthma
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2009-02-04
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT00543686
- Locations
- 🇩🇪
Goethe University, Department of Pulmonology, Frankfurt, Hessen, Germany
Effect of Montelukast on the Expression and Variation of TGF-β for Children With Mild Persistent Asthma
- Conditions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2011-07-27
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 112
- Registration Number
- NCT00536705
- Locations
- 🇨🇳
Shanghai First People'S Hospital, Shanghai, Shanghai, China
Montelukast in Acute RSV Bronchiolitis
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2007-09-05
- Lead Sponsor
- Ziv Hospital
- Target Recruit Count
- 51
- Registration Number
- NCT00524693
Montelukast With Status Asthmaticus, Ages 6-18
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2008-12-16
- Target Recruit Count
- 52
- Registration Number
- NCT00494572
- Locations
- 🇺🇸
Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.